"studyVersion","studyRationale","studyAcronym","uuid:ID","id","studyTitle"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","LZZT","3bd4f5e7-4335-4788-a370-4b1de84be5a9","StudyVersion_1","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease"
